1-3 of 3
Becker Hewes, MD
Close
Sort by
Journal Articles

Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia- Preliminary Results From a Phase I Study

Geoffrey L. Uy, MD, David Avigan, MD, Jorge E. Cortes, Pamela S. Becker, MD, PhD, Robert W. Chen, MD, Jane L. Liesveld, MD, Becker Hewes, MD, Don Johns, Harry Paul Erba, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 82.
https://doi.org/10.1182/blood.V118.21.82.82
Published: 2011
Journal Articles

Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic Leukemia

Leslie Andritsos, MD, John C. Byrd, MD, Jeffrey A. Jones, MD, MPH, Becker Hewes, MD, Thomas J. Kipps, MD, PhD, Frank J Hsu, Jan A. Burger, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 2450.
https://doi.org/10.1182/blood.V116.21.2450.2450
Published: 2010
Journal Articles

A Phase 1/2 Study of SKI-606, a Dual Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) Relapsed, Refractory or Intolerant of Imatinib.

Jorge Cortes, MD, Hagop M. Kantarjian, MD, Michele Baccarani, MD, Tim H. Brummendorf, MD, Delong Liu, MD, Gert Ossenkoppele, MD, Angela D.G. Volkert, BA, Becker Hewes, MD, Laurence Moore, MD, PhD, Charles Zacharchuk, MD, PhD, Carlo Gambacorti, MD
Journal: Blood
Blood (2006) 108 (11): 168.
https://doi.org/10.1182/blood.V108.11.168.168
Published: 2006